Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Analytics for clinical development strategy: Integrated optimization of an oncology program
    15 November 2024

    Analytics for clinical development strategy: Integrated optimization of an oncology program

    Achieving a return on invested capital (ROIC) that exceeds the cost of capital remains a challenge for pharmaceutical R&D. To make progress, there needs to be consistent and rigorous modeling of the clinical and commercial determinants of ROIC. In the second of three articles, CRA’...

    CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?
    15 November 2024

    CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?

    Aduhelm was the first FDA-approved disease-modifying treatment for Alzheimer’s, sparking debate among providers, regulators, and patients. Aduhelm received a controversial accelerated approval from the FDA in June 2021, a decision that balanced the lack of consensuses among the scientif...

    Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D
    5 November 2024

    Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D

    Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This...

    Infertility - A public health concern
    4 November 2024

    Infertility - A public health concern

    The World Health Organization (WHO) estimates that one out of six people globally are impacted by the inability to conceive a child. Over the last decade, countries around the world have seen a decline in total fertility rates, most notably in economically developed countries withi...

    Winners of the OBN Awards 2024
    21 November 2024

    Shining a light on the life sciences

    The OBN Awards struck an optimistic tone as the best of the UK’s life sciences industry was celebrated Abingdon, UK, 21 November 2024: – OBN (UK) Ltd is thrilled to announce the winners of the prestigious OBN Awards 2024. This was the 16th year of the Awards, which OBN (UK) Ltd, the no...

    logo
    22 November 2024

    Medicilon delivers fast turnaround time to meet your FDA submission deadline for SEND Format Conversion

    Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data...

    Glox Therapeutics supported by PACE
    20 November 2024

    Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens

    Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects Glasgow, UK, 20 November...

    COPD
    20 November 2024

    COPD management: a critical look at gaps in pharmaceutical innovation

    Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care. ...

    Spheroid confocal spinning disk (left) and holotomography acquisitions (right).
    20 November 2024

    CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform

    First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22nd November, Toledo, Spain) Rome, IT, 20 November, 2024: CrestOptics S.p.A., a manufacturer of high...

    The Tagomics team
    20 November 2024

    Tagomics announces a multiomic profiling co-marketing agreement with Agilent

    Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis ...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 108
    • Page 109
    • Current page 110
    • Page 111
    • Page 112
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS